A Novel Serum Marker, Total Prostate Secretory Protein of 94 Amino Acids, Improves Prostate Cancer Detection and Helps Identify High Grade Cancers at Diagnosis
- 1 April 2006
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 175 (4) , 1291-1297
- https://doi.org/10.1016/s0022-5347(05)00695-6
Abstract
New biomarkers for prostate cancer are needed. We determined whether a novel serum marker, total PSP94 can be used to accomplish these goals. We conducted a case-control study of 1,212 men with no previous history of prostate cancer and who underwent a prostate biopsy from 1998 to 2000 because of an increased PSA or an abnormal DRE. Serum PSP94 levels were assessed using a sandwich enzyme-linked immunosorbent assay technique. Cases were patients with prostate cancer, and controls were patients who had no evidence of cancer. Multivariate logistic regression analysis was used to determine whether or not PSP94 levels improved the predictive value for prostate cancer. Of the 1,212 men 596 (49.2%) had cancer detected. The median PSP94 level was significantly lower among cases (2.60 ng/ml) than among controls (3.40 ng/ml, p <0.0001). The adjusted odds ratios for the presence of prostate cancer for patients with the lowest quartile of PSP94, compared to patients in the highest quartile was 2.70 (95% CI 1.8 - 4.0, p <0.0001). Among a subgroup of 649 men in whom PSA had a low predictive value (PSA less than 20 ng/ml, normal DRE and less than 70 years), 260 (40.1%) were found to have cancer. In this subgroup total PSP94 levels helped discriminate between patients with high grade disease (Gleason score 8 or more, median 1.90 ng/ml), moderate grade disease (Gleason score 7, median 2.34 ng/ml) and low grade disease (Gleason score 6 or less, median 2.60 ng/ml, p = 0.007). PSA and the FTPSA were not able to distinguish between patients with different grades in this group. Patients with low total PSP94 levels had a high probability for having prostate cancer detected at biopsy. The total PSP94 level was able to help identify patients with high grade disease among a subset of patients in whom PSA and FTPSA are least informative.Keywords
This publication has 18 references indexed in Scilit:
- Identification, purification and characterization of a novel human blood protein with binding affinity for prostate secretory protein of 94 amino acidsBiochemical Journal, 2004
- THE PROSTATE SPECIFIC ANTIGEN ERA IN THE UNITED STATES IS OVER FOR PROSTATE CANCER: WHAT HAPPENED IN THE LAST 20 YEARS?Journal of Urology, 2004
- SERUM PRO-PROSTATE SPECIFIC ANTIGEN PREFERENTIALLY DETECTS AGGRESSIVE PROSTATE CANCERS IN MEN WITH 2 TO 4 NG/ML PROSTATE SPECIFIC ANTIGENJournal of Urology, 2004
- Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per MilliliterNew England Journal of Medicine, 2004
- Complexed Prostate Specific Antigen Improves Specificity for Prostate Cancer Detection: Results of a Prospective Multicenter Clinical TrialJournal of Urology, 2003
- Single Nucleotide Polymorphism of the Human Kallikrein-2 Gene Highly Correlates With Serum Human Kallikrein-2 Levels and in Combination Enhances Prostate Cancer DetectionJournal of Clinical Oncology, 2003
- Serum bound forms of PSP94 (prostate secretory protein of 94 amino acids) in prostate cancer patientsJournal of Cellular Biochemistry, 1999
- Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosisThe Prostate, 1999
- American Cancer Society guidelines for the early detection of prostate cancerCancer, 1997
- Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the ProstateNew England Journal of Medicine, 1987